Drug Profile
Research programme: peripheral neuropathy therapeutics - SmartZyme BioPharma
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator SmartZyme Biopharma
- Class RNA
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peripheral nervous system diseases
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Peripheral-nervous-system-diseases in Israel (Parenteral)
- 07 Jul 2017 Early research in Peripheral nervous system diseases in Israel (Parenteral)